All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine
Therapeutic Area: Immunology Product Name: Diregura
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: LTL Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2020
Details:
LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2020
Details:
Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones.